{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:09:54Z","timestamp":1784578194401,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":4534,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1017\/s1041610212000579","type":"journal-article","created":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T09:04:50Z","timestamp":1342083890000},"page":"S10-S17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S1","title":["Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention"],"prefix":"10.1016","volume":"24","author":[{"given":"Harald","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610212000579_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/alzrt2","article-title":"Alzheimer's disease therapeutic research: the path forward","volume":"1","author":"Aisen","year":"2009","journal-title":"Alzheimer's Research and Therapy"},{"key":"10.1017\/S1041610212000579_bb0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","article-title":"The rise and fall of Dimebon","volume":"23","author":"Bezprozvanny","year":"2010","journal-title":"Drug News Perspectives"},{"key":"10.1017\/S1041610212000579_bb0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.biopsych.2010.09.020","article-title":"What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?","volume":"68","author":"Cummings","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1017\/S1041610212000579_bb0025","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2008.683","article-title":"Ginkgo biloba for prevention of dementia: a randomized controlled trial","volume":"300","author":"on behalf of the Ginkgo Evaluation of Memory (GEM) Study Investigators","year":"2008","journal-title":"JAMA"},{"key":"10.1017\/S1041610212000579_bb0030","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1017\/S1041610212000579_bb0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1017\/S1041610212000579_bb0040","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/archneurol.2009.106","article-title":"Progression of mild cognitive impairment to dementia in clinic vs. community-based cohorts","volume":"66","author":"Farias","year":"2009","journal-title":"Archives of Neurology"},{"key":"10.1017\/S1041610212000579_bb0045","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nature Reviews in Drug Discovery"},{"key":"10.1017\/S1041610212000579_bb0050","doi-asserted-by":"crossref","first-page":"16755","DOI":"10.1523\/JNEUROSCI.4521-10.2010","article-title":"Reimagining Alzheimer's disease: an age-based hypothesis","volume":"30","author":"Herrup","year":"2010","journal-title":"Journal of Neuroscience"},{"key":"10.1017\/S1041610212000579_bb0055","unstructured":"Ipsen (2010). Encouraging results of GuidAge\u00ae, large scale European trial conducted in the prevention of Alzheimer's Dementia. Press release. Available at: http:\/\/www.ipsen.com\/sites\/default\/files\/communiques-presse\/PR%20GuidAge%20Results%20FINAL%20EN.pdf; last accessed 6 March 2012."},{"key":"10.1017\/S1041610212000579_bb0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet"},{"key":"10.1017\/S1041610212000579_bb0065","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiology of Aging"},{"key":"10.1017\/S1041610212000579_bb0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's and Dementia"},{"key":"10.1017\/S1041610212000579_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.pneurobio.2011.07.004","article-title":"Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention","volume":"95","author":"Trojanowski","year":"2011","journal-title":"Progress in Neurobiology"},{"issue":"Suppl. 2","key":"10.1017\/S1041610212000579_bb0080","first-page":"S23","article-title":"Results of Guidage: a 5-year placebo-controlled study on the efficacy of EGb761 120 mg to prevent or delay Alzheimer's dementia onset in elderly subjects with memory complaint","volume":"14","author":"Vellas","year":"2010","journal-title":"Journal of Nutrition, Health and Aging"},{"key":"10.1017\/S1041610212000579_bb0085","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change","volume":"73","author":"on behalf of the Alzheimer's Disease Neuroimaging Initiative","year":"2009","journal-title":"Neurology"},{"key":"10.1017\/S1041610212000579_bb0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","article-title":"Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study","volume":"8","author":"Visser","year":"2009","journal-title":"Lancet Neurology"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224021367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224021367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610212000579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:02:12Z","timestamp":1736503332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224021367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":17,"alternative-id":["S1041610224021367"],"URL":"https:\/\/doi.org\/10.1017\/s1041610212000579","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610212000579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Copyright \u00a9 International Psychogeriatric Association 2012. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}